Fecal Occult Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, and Immuno-FOB ELISA Test), By End User (Hospitals, Clinical Diagnostic Laboratories, and Physicians Office Laboratories) and Region Forecast 2020-2031

Fecal Occult Testing Market Dynamics

Colorectal cancer (CRC) is already the third leading cause of cancer death in the world, and its incidence is steadily rising in developing nations. Also known as colorectal adenocarcinoma, CRC usually emerges from the glandular, epithelial cells of the large intestine. Cancer arises when certain cells of the epithelium acquire a series of genetic or epigenetic mutations that confer on them a selective advantage. With abnormally heightened replication and survival, these hyper-proliferative cells give rise to a benign adenoma, which may then evolve into carcinoma and metastasize over decades. Colorectal cancer is the third most common cancer diagnosed in both men and women each year in the United States, excluding skin cancer. In 2022, an estimated 151,030 adults in the United States will be diagnosed with colorectal cancer.

These numbers include 106,180 new cases of colon cancer (54,040 men and 52,140 women) and 44,850 new cases of rectal cancer (26,650 men and 18,200 women). Worldwide, colorectal cancer is the third most diagnosed cancer. An estimated 1,880,725 people were diagnosed with colorectal cancer in 2020. These numbers include 1,148,515 colon cancer cases and 732,210 rectal cancer cases. Diagnosis of colon cancer at an early stage can help in controlling mortality. Availability of fecal occult blood test products in online stores and improvement in direct-to-consumer laboratory testing are the trending factors expected to provide lucrative growth opportunities to the market during the forecast period.